Prognostic value of serum levels of tumor necrosis factor-alpha in patients with heart failure;Valor pronóstico de los niveles séricos del factor de necrosis tumoral alfa en pacientes con insuficiencia cardíaca

Revista Espanola de Cardiologia

Volumn 56, Issue 2, 2003, Pages 160-167

  Torrent Jordán, Alejandro J ^c   Esteban, Ángel ^a   García, Miguel ^c   Monmeneu, José V ^c   Espinosa, Dolores ^c   Reyes, Fernando ^c   Luján, Juan ^c   Climent, Vicente ^b   Marín, Francisco ^b   García de Burgos, Fernando ^c  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^c NONE

Author keywords

Cytokines; Heart failure; Prognosis

Indexed keywords

CARBON DIOXIDE; CYTOKINE; OXYGEN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE; AGED; ARTICLE; BLOOD ANALYSIS; CARBON DIOXIDE TENSION; CLINICAL ARTICLE; COMMUNITY HOSPITAL; CONTROLLED STUDY; DISEASE SEVERITY; DYNAMOMETRY; ECHOCARDIOGRAPHY; EXERCISE TEST; FEMALE; FOLLOW UP; HEART DILATATION; HEART FAILURE; HEART TRANSPLANTATION; HOSPITAL ADMISSION; HUMAN; MALE; MEDICAL ASSESSMENT; MEDICAL DOCUMENTATION; MORTALITY; MUSCLE STRENGTH; OXYGEN CONSUMPTION; PROGNOSIS; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; TREADMILL;

EID: 0346666705     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13043222     Document Type: Article

References (30)

1. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in congestive heart failure. N Engl J Med 1990;323:236-41.
2. Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997;96:526-34.
3. Kalman J, Levine B, Mayer L, Penn J, Kubin ML, Packer M. Prognostic importance of circulating neopterin in heart failure: evidence for monocyte activation in patients with cardiac cachexia. Circulation 1990;82(Suppl 3):315.
4. Flores EA, Bistrian BR, Pomposelli JJ, Dinarello CA, Blackburn GL, Istfan NW. Infusion of tumor necrosis factor/cachectin produces muscle catabolism in the rat: asynergistic effect with interleukin-1. J Clin Invest 1989;83:1614-22.
5. Torre-Amione G, Kapadia S, Lee J, Bies RD, Lebovitz R, Mann DL. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 1995;92:1487-93.
6. Odeh M. Tumor necrosis factor-alpha as a myocardial depressant substance. Int J Cardiol 1993;42:231-8.
7. Herrera-Garza EH, Stetson SJ, Cubillos-Garzón A, Vooletich MT, Farmer JA, Torre-Amione G. Tumor necrosis factor-alpha. A mediator of disease progression in the failing human heart. Chest 1999;115:1170-4.
8. Herrera Garza EH, Herrera Garza JL, Rodríguez González H, Treviño Treviño A, Ibarra Flores M, Torre Amione G. Importancia del factor de necrosis tumoral alfa en la patogenia de la insuficiencia cardíaca. Rev Esp Cardiol 2002;55:61-6.
9. Dutka DP, Elborn JS, Delamere F, Shale DJ, Morris GK. Tumor necrosis factor alpha in severe congestive cardiac failure. B Heart J 1993;70:141-3.
10. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Disfunction (SOLVD). J Am Coll Cardiol 1996;27:1201-6.
11. Rauchhaus M, Doehner W, Francis D, Davos C, Kemp M, Liebenthal C, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000;102:3060-7.
12. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokin receptors in advanced heart failure. An analysis of the cytokine database from the Vesnarinone Trial (VEST). Circulation 2001;103:2055-9.
13. Mancini D, Eisen H, Kussmaul W, Mull R, Edmunds L, Wilson J. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation of ambulatory patients with heart failure. Circulation 1991;83:778-86.
14. Stevenson L, Steimle A, Chelimsky-Fallick C, Fonarow G, Hamilton M, Moriguchi J, et al. Outcomes predicted by peak oxygen consumption during evaluation of 333 patients with advanced heart failure. Circulation 1993;88:A94.
15. Haywood GA, Rickenbacher PR, Trindade PT, Vagelos RH, Oyer P, Fowler MB. Deaths in patients awaiting heart transplantation: the need to identify high risk category two patients. Circulation 1994;90(Suppl 1):360.
16. Ponikowski P, Francis DP, Piepoli MF, Davies LC, Chua TP, Davos CH, et al. Enhanced ventilatory response to exercise in patients with chronic heart failure and preserved exercise tolerance. Marker of abnormal cardiorrespiratory reflex control and predictor of poor prognosis. Circulation 2001;103:967-72.
17. Ferrari R, Bachetti T, Confortini R, Opasich C, Febo O, Corti A, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995;92: 1479-86.
18. Munger MA, Johnson B, Amber IJ, Callahan KS, Gilbert EM. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996;77:723-7.
19. Metra M, Raccagni D, Carini G, Orzan F, Papa A, Nodari S, et al. Ventilatory and arterial blood gas changes during exercise in heart failure. In: Wasserman K, editor. Exercise gas exchange in heart failure. Armonk: Futura Publishing Company, Inc., 1996; p. 125-43.
20. Balogun JA, Akomolafe CT, Amusa LO. Grip strength: effects of testing posture and elbow position. Arch Phys Med Rehabil 1991;72:280-3.
21. Milani RV, Mehra MR, Endres S, Eigler A, Cooper ES, Lavie CJ, et al. The clinical relevance of circulating tumor necrosis factor-alpha in acute decompensated chronic heart failure without caquexia. Chest 1996;110:992-5.
22. Testa M, Yeh M, Lee P, Fanelli R, Loperfido F, Berman JW, et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coranary artery disease or hypertension. J Am Coll Cardiol 1996;28:964-71.
23. Prichett G, Cohen HJ, Rao KM, Cobb F, Sullivan M, Currie MS. Tumor necrosis factor, natural killer activity and other measures of immume function and inflammatin in elderly men with heart failure. Gerontology 1995;41:45-56.
24. Massie BM, Simonini A, Sahgal P, Wells L, Dudley GA. Relation of systemic and local muscle exercise capacity to skeletal muscle characteristics in men with congestive heart failure. J Am Coll Cardiol 1996;27:140-5.
25. Volterrani M, Clark AL, Ludman PF, Swan JW, Adamopoulos S, Piepoli M, et al. Predictors of exercise capacity in chronic heart failure. Eur Heart J 1994;15:801-9.
26. Dalla Libera L, Ravara B, Angelini A, Rossini K, Sandri M, Thiene G, et al. Beneficial effects on skeletal muscle of the angiotensin II type I receptor blocker irbesartan in experimental heart failure. Circulation 2001;103:2195.
27. Cicoira M, Bolger A, Doehner W, Rauchhaus M, Davos C, Sharma R, et al. High tumor necrosis factor levels are associated with exercise intolerance and neurohormonal activation in chronic heart failure patients [resumen]. J Am Coll Cardiol 2001;37(Suppl A):190.
28. Chua TP, Anker SD, Harrington D, Coats AJS. Inspiratory muscle strength is a determinant of maximum oxygen consumption in chronic heart failure. Br Heart J 1995;74:381-5.
29. Vidal B, Roig E, Pérez-Villa F, Orús J, Pérez J, Jiménez V, et al. Valor pronóstico de los niveles de citocinas y neurohormonas en la insuficiencia cardíaca severa. Rev Esp Cardiol 2002;55:481-6.
30. Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996;93:704-11.